Regardless of the cause of a disease, most diseases involve gene dysregulation. Omega Therapeutics is developing a new class of programmable, epigenomic, mRNA medicines designed to make specific epigenetic changes and correct abnormal gene expression to treat or cure diseases. We spoke to Mahesh Karande, president and CEO of Omega Therapeutics, about its pipeline of mRNA therapies, how they work, and its recently announced collaboration with Novo Nordisk to develop an epigenomic controller to treat obesity.
Engineering Safer and More Effective Cell Therapies
Changing Drug Discovery for Neuropsychiatric Disorders with Phenotypic Screens
Using Virtual Reality-Guided Mindfulness to Treat Chronic Pain in Cancer Patients
Activating the Adaptive and Innate Immune Systems to Fight Cancer
A Longevity Fund Focused on Young Companies
Learning from “Elite” Responders to Develop Better Immunotherapies
Bringing Precision Medicine to the Treatment of Obesity
Expanding the Promise of RNA Therapies
Triggering a Systemic Immune Response Against Cancer
Targeting RNA Dysregulation in Cancer
Building a Pipeline of Next-Generation Kinase Inhibitors
Rethinking How Cell and Gene Therapies Are Made to Improve Accessibility
Developing Next-Generation Radiopharmaceuticals
Why Great Science and Data Aren’t Enough
Targeting Sugars that Let Cancers Evade the Immune System
Engineering Stem Cells to Withstand Targeted Therapies
Targeting a Convergence of Signaling Pathways that Drive the Growth and Spread of Cancer
Moving from Preservation to Restoration with Off-the-Shelf Cell Therapies
Using Gene Therapies to Treat Chronic, Inflammatory Conditions
Unlocking the Full Potential of Antibody Therapies
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Ground Truths